From Humira to Keytruda: The Blueprint for Surviving the “Composition-of-Matter Cliff”
The composition-of-matter cliff isn’t a metaphor. It’s a calendar.
For years, biopharma companies have treated patent life like a runway—extend it, manage it, and ke…

Pharma’s “patent cliff” isn’t just about expiring patents. It’s about how those patents are written.
For years, the industry has treated the patent cliff like a calendar problem: a handful of years, a wave of generics, a predictable hit to revenue. But…

The Patent Dance Is No Longer a Game of Guessing—It’s a Game of Timing.
If you’ve been anywhere near biosimilars, you’ve heard the phrase: the patent dance. It sounds procedural—almost bureaucratic. But in practice, it’s where fortunes are made (or qui…

{
“error”: {
“message”: “You exceeded your current quota, please check your plan and billing details. For more information on this error, read the docs: https://platform.openai.com/docs/guides/error-codes/api-errors.”,
“type”: “insufficient_quota”,
“pa…

{
“error”: {
“message”: “You exceeded your current quota, please check your plan and billing details. For more information on this error, read the docs: https://platform.openai.com/docs/guides/error-codes/api-errors.”,
“type”: “insufficient_quota”,
“pa…

Blockbuster patents aren’t just legal documents—they’re engineering blueprints.
If you’ve ever wondered how competitors “magically” arrive at a viable design-around for a blockbuster drug, the answer is rarely magic. It’s usually forensics: a discipl…

Patent risk isn’t just a legal problem—it’s a board-level governance problem.
For years, pharma leaders treated IP litigation like a downstream event: something handled by counsel, managed by outside firms, and resolved on a timeline that rarely matche…

{
“error”: {
“message”: “You exceeded your current quota, please check your plan and billing details. For more information on this error, read the docs: https://platform.openai.com/docs/guides/error-codes/api-errors.”,
“type”: “insufficient_quota”,
“pa…

Pharma forensics is the new competitive intelligence.
Most people think formulation patents are “just chemistry.” In reality, they’re often the most strategic documents in a company’s lifecycle playbook—quietly encoding timelines, manufacturing const…

Designing Around the Moat: How Generic Developers Can Win the Secondary-Patent Game
In generic drug development, the first patent is rarely the whole story.
Most teams plan their strategy around the “primary” patent landscape—mechanism-of-action, compo…